RU2007104774A - Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы - Google Patents
Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы Download PDFInfo
- Publication number
- RU2007104774A RU2007104774A RU2007104774/15A RU2007104774A RU2007104774A RU 2007104774 A RU2007104774 A RU 2007104774A RU 2007104774/15 A RU2007104774/15 A RU 2007104774/15A RU 2007104774 A RU2007104774 A RU 2007104774A RU 2007104774 A RU2007104774 A RU 2007104774A
- Authority
- RU
- Russia
- Prior art keywords
- combination
- combination according
- dosage form
- unit dosage
- ritonavir
- Prior art date
Links
- 230000036436 anti-hiv Effects 0.000 title claims abstract 3
- 102100034343 Integrase Human genes 0.000 title 1
- 102000035195 Peptidases Human genes 0.000 title 1
- 108091005804 Peptidases Proteins 0.000 title 1
- 239000004365 Protease Substances 0.000 title 1
- 108010092799 RNA-directed DNA polymerase Proteins 0.000 title 1
- 239000003112 inhibitor Substances 0.000 title 1
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical class OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 claims abstract 5
- NCDNCNXCDXHOMX-UHFFFAOYSA-N Ritonavir Natural products C=1C=CC=CC=1CC(NC(=O)OCC=1SC=NC=1)C(O)CC(CC=1C=CC=CC=1)NC(=O)C(C(C)C)NC(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-UHFFFAOYSA-N 0.000 claims abstract 5
- 229960000311 ritonavir Drugs 0.000 claims abstract 5
- NCDNCNXCDXHOMX-XGKFQTDJSA-N ritonavir Chemical compound N([C@@H](C(C)C)C(=O)N[C@H](C[C@H](O)[C@H](CC=1C=CC=CC=1)NC(=O)OCC=1SC=NC=1)CC=1C=CC=CC=1)C(=O)N(C)CC1=CSC(C(C)C)=N1 NCDNCNXCDXHOMX-XGKFQTDJSA-N 0.000 claims abstract 5
- 229960004556 tenofovir Drugs 0.000 claims abstract 5
- VCMJCVGFSROFHV-WZGZYPNHSA-N tenofovir disoproxil fumarate Chemical compound OC(=O)\C=C\C(O)=O.N1=CN=C2N(C[C@@H](C)OCP(=O)(OCOC(=O)OC(C)C)OCOC(=O)OC(C)C)C=NC2=C1N VCMJCVGFSROFHV-WZGZYPNHSA-N 0.000 claims abstract 5
- 208000031886 HIV Infections Diseases 0.000 claims abstract 4
- 230000002265 prevention Effects 0.000 claims abstract 4
- 229960005107 darunavir Drugs 0.000 claims abstract 3
- CJBJHOAVZSMMDJ-HEXNFIEUSA-N darunavir Chemical compound C([C@@H]([C@H](O)CN(CC(C)C)S(=O)(=O)C=1C=CC(N)=CC=1)NC(=O)O[C@@H]1[C@@H]2CCO[C@@H]2OC1)C1=CC=CC=C1 CJBJHOAVZSMMDJ-HEXNFIEUSA-N 0.000 claims abstract 3
- 239000008194 pharmaceutical composition Substances 0.000 claims abstract 3
- 239000002552 dosage form Substances 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 208000037357 HIV infectious disease Diseases 0.000 claims 3
- 208000033519 human immunodeficiency virus infectious disease Diseases 0.000 claims 3
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 claims 3
- 239000003814 drug Substances 0.000 claims 2
- 238000004519 manufacturing process Methods 0.000 claims 1
- 239000000203 mixture Substances 0.000 claims 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
- A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
- A61K31/343—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide condensed with a carbocyclic ring, e.g. coumaran, bufuralol, befunolol, clobenfurol, amiodarone
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
- A61K31/425—Thiazoles
- A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7042—Compounds having saccharide radicals and heterocyclic rings
- A61K31/7052—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides
- A61K31/706—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom
- A61K31/7064—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines
- A61K31/7076—Compounds having saccharide radicals and heterocyclic rings having nitrogen as a ring hetero atom, e.g. nucleosides, nucleotides containing six-membered rings with nitrogen as a ring hetero atom containing condensed or non-condensed pyrimidines containing purines, e.g. adenosine, adenylic acid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
- A61P31/12—Antivirals
- A61P31/14—Antivirals for RNA viruses
- A61P31/18—Antivirals for RNA viruses for HIV
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Medicinal Chemistry (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Chemical & Material Sciences (AREA)
- Epidemiology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Molecular Biology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Organic Chemistry (AREA)
- General Chemical & Material Sciences (AREA)
- Oncology (AREA)
- Virology (AREA)
- Communicable Diseases (AREA)
- Tropical Medicine & Parasitology (AREA)
- Engineering & Computer Science (AREA)
- Bioinformatics & Cheminformatics (AREA)
- AIDS & HIV (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Aiming, Guidance, Guns With A Light Source, Armor, Camouflage, And Targets (AREA)
Claims (14)
1. Анти-ВИЧ комбинация, включающая (i) тенофовир или его дизопроксилфумаратное производное, (ii) ритонавир и (iii) ТМC114.
2. Комбинация по п.1, где компоненты комбинации находятся в виде единой или отдельной фармацевтической(их) композиции(й).
3. Комбинация по п.1, где дизопроксилфумарат тенофовира входит в состав фармацевтической стандартной лекарственной формы, содержащей примерно 300 мг дизопроксилфумарата тенофовира на стандартную лекарственную форму.
4. Комбинация по любому из предшествующих пунктов, где ритонавир входит в состав фармацевтической стандартной лекарственной формы, содержащей от 100 до 400 мг ритонавира на стандартную лекарственную форму.
5. Комбинация по п.1, где ТМС114 входит в состав фармацевтической стандартной лекарственной формы, содержащей от 400 до 1200 мг ТМС114 на стандартную лекарственную форму.
6. Фармацевтическая композиция, включающая комбинацию по п.1.
7. Комбинация по п.1 для применения в качестве лекарственного средства.
8. Комбинация по п.7 для применения с целью профилактики или лечения ВИЧ инфекции.
9. Применение комбинации по п.1 для получения лекарственного средства для профилактики или лечения ВИЧ инфекции.
10. Способ профилактики или лечения ВИЧ инфекции у человека, который включает введение указанному человеку терапевтически эффективного количества комбинации по п.1.
11. Способ по п.10, где дизопроксилфумарат тенофовира вводят в суточной дозе, составляющей примерно 300 мг.
12. Способ по п.10, где ритонавир вводят в суточной дозе, составляющей от 100 до 400 мг.
13. Способ по п.10, где ТМС114 вводят в суточной дозе от 400 до 1200 мг.
14. Способ по п.10, где комбинацию вводят в виде фармацевтической композиции.
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP04103256 | 2004-07-08 | ||
| EP04103256.6 | 2004-07-08 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| RU2007104774A true RU2007104774A (ru) | 2008-08-20 |
| RU2368380C2 RU2368380C2 (ru) | 2009-09-27 |
Family
ID=34929311
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| RU2007104774/15A RU2368380C2 (ru) | 2004-07-08 | 2005-07-08 | Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы |
Country Status (19)
| Country | Link |
|---|---|
| US (1) | US20070208009A1 (ru) |
| EP (1) | EP1765337B1 (ru) |
| JP (1) | JP2008505870A (ru) |
| CN (1) | CN1984654A (ru) |
| AT (1) | ATE406161T1 (ru) |
| AU (1) | AU2005261701A1 (ru) |
| BR (1) | BRPI0513051A (ru) |
| CA (1) | CA2572551A1 (ru) |
| DE (1) | DE602005009366D1 (ru) |
| DK (1) | DK1765337T3 (ru) |
| ES (1) | ES2313394T3 (ru) |
| HR (1) | HRP20080612T3 (ru) |
| MX (1) | MXPA06014930A (ru) |
| NZ (1) | NZ551841A (ru) |
| PL (1) | PL1765337T3 (ru) |
| RU (1) | RU2368380C2 (ru) |
| SI (1) | SI1765337T1 (ru) |
| WO (1) | WO2006005720A1 (ru) |
| ZA (1) | ZA200700176B (ru) |
Families Citing this family (12)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA2585576A1 (en) * | 2004-11-16 | 2006-05-26 | Boehringer Ingelheim International Gmbh | Method for treating hiv infection through co-administration of tipranavir and darunavir |
| WO2009056818A1 (en) * | 2007-10-29 | 2009-05-07 | Cipla Limited | Novel antiretroviral combination |
| PA8809601A1 (es) * | 2007-12-24 | 2009-07-23 | Cipla Ltd | Combinación anti-retroviral |
| CN102876714A (zh) * | 2011-09-07 | 2013-01-16 | 深圳市易瑞生物技术有限公司 | 用慢病毒检测hiv耐药表型 |
| WO2013057469A1 (en) * | 2011-10-20 | 2013-04-25 | Cipla Limited | Pharmaceutical antiretroviral compositions |
| BR112015006558A2 (pt) * | 2012-10-23 | 2017-07-04 | Cipla Ltd | composição farmacêutica, processo para preparar uma composição farmacêutica, uso de uma composição farmacêutica, e, método para prevenir ou tratar doenças causadas por retrovírus |
| WO2014184553A1 (en) * | 2013-05-15 | 2014-11-20 | Cipla Limited | Pharmaceutical antiretroviral compositions |
| MX2016002560A (es) * | 2013-08-29 | 2016-10-26 | Teva Pharma | Forma de dosificacion unitaria que comprende emtricitabina, tenofovir, darunavir y ritonavir y un comprimido monolitico que comprende darunavir y ritonavir. |
| EP3129009A1 (en) * | 2014-04-08 | 2017-02-15 | Teva Pharmaceutical Industries Ltd | Unit dosage form comprising emtricitabine, tenofovir, darunavir and ritonavir |
| GB201509431D0 (en) * | 2015-06-01 | 2015-07-15 | Equigerminal Sa | Antiviral composition |
| US10213507B2 (en) * | 2017-03-10 | 2019-02-26 | The Florida International University Board Of Trustees | Compositions and methods for treating HIV-associated neurocognitive disorders |
| RU2662160C9 (ru) * | 2017-07-03 | 2018-10-22 | Александрович Иващенко Андрей | Комбинированный лекарственный препарат для терапии вирусных инфекций |
Family Cites Families (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TWI286476B (en) * | 2001-12-12 | 2007-09-11 | Tibotec Pharm Ltd | Combination of cytochrome P450 dependent protease inhibitors |
-
2005
- 2005-07-08 SI SI200530488T patent/SI1765337T1/sl unknown
- 2005-07-08 PL PL05774136T patent/PL1765337T3/pl unknown
- 2005-07-08 HR HR20080612T patent/HRP20080612T3/xx unknown
- 2005-07-08 NZ NZ551841A patent/NZ551841A/en not_active IP Right Cessation
- 2005-07-08 JP JP2007519807A patent/JP2008505870A/ja not_active Withdrawn
- 2005-07-08 EP EP05774136A patent/EP1765337B1/en not_active Expired - Lifetime
- 2005-07-08 MX MXPA06014930A patent/MXPA06014930A/es active IP Right Grant
- 2005-07-08 AU AU2005261701A patent/AU2005261701A1/en not_active Abandoned
- 2005-07-08 US US11/571,599 patent/US20070208009A1/en not_active Abandoned
- 2005-07-08 WO PCT/EP2005/053266 patent/WO2006005720A1/en not_active Ceased
- 2005-07-08 CA CA002572551A patent/CA2572551A1/en not_active Abandoned
- 2005-07-08 CN CNA2005800230750A patent/CN1984654A/zh active Pending
- 2005-07-08 DK DK05774136T patent/DK1765337T3/da active
- 2005-07-08 ES ES05774136T patent/ES2313394T3/es not_active Expired - Lifetime
- 2005-07-08 DE DE602005009366T patent/DE602005009366D1/de not_active Expired - Fee Related
- 2005-07-08 AT AT05774136T patent/ATE406161T1/de not_active IP Right Cessation
- 2005-07-08 RU RU2007104774/15A patent/RU2368380C2/ru not_active IP Right Cessation
- 2005-07-08 BR BRPI0513051-4A patent/BRPI0513051A/pt not_active IP Right Cessation
-
2007
- 2007-01-05 ZA ZA200700176A patent/ZA200700176B/en unknown
Also Published As
| Publication number | Publication date |
|---|---|
| ZA200700176B (en) | 2008-04-30 |
| EP1765337A1 (en) | 2007-03-28 |
| HRP20080612T3 (hr) | 2009-01-31 |
| ES2313394T3 (es) | 2009-03-01 |
| DE602005009366D1 (de) | 2008-10-09 |
| PL1765337T3 (pl) | 2009-02-27 |
| NZ551841A (en) | 2009-04-30 |
| AU2005261701A1 (en) | 2006-01-19 |
| CN1984654A (zh) | 2007-06-20 |
| BRPI0513051A (pt) | 2008-04-22 |
| WO2006005720A1 (en) | 2006-01-19 |
| JP2008505870A (ja) | 2008-02-28 |
| SI1765337T1 (sl) | 2009-02-28 |
| EP1765337B1 (en) | 2008-08-27 |
| MXPA06014930A (es) | 2007-02-28 |
| ATE406161T1 (de) | 2008-09-15 |
| US20070208009A1 (en) | 2007-09-06 |
| RU2368380C2 (ru) | 2009-09-27 |
| DK1765337T3 (da) | 2009-01-05 |
| CA2572551A1 (en) | 2006-01-19 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| RU2329050C2 (ru) | Комбинация ингибиторов цитохром-р450-зависимых протеаз | |
| RU2355700C9 (ru) | Новые пептиды как ингибиторы ns3-серинпротеазы вируса гепатита с | |
| AR035927A1 (es) | Compuesto de lactama (n)-((s)-2-hidroxi-3-metilbutiril)-1-(l-alaninil)-(s)-1-amino-3-metil-4,5,6,7-tetrahidro-2h-3-benzazepin-2-ona , composicion farmaceutica que lo comprende, procedimiento para la inhibicion de la liberacion de peptido b-amiloide y/o su sintesis que lo emplea y su uso para la fabr | |
| CR8352A (es) | Formulaciones farmaceuticas, procedimientos y pautas de dosificacion para el tratamiento y prevencion de sindromes coronarios agudos | |
| CY1115484T1 (el) | Ενωσεις, συνθεσεις και μεθοδοι για την θεραπεια αμυλοειδικων ασθενειων και συνουκλεϊνοπαθειων, οπως νοσος alzheimer, διαβητης τυπου 2 και νοσος parkinson | |
| SE9804314D0 (sv) | New pharmaceutical formulation | |
| DE50203456D1 (de) | Deuterierte 3-piperidinopropiophenone sowie diese verbindungen enthaltende arzneimittel | |
| WO2005065069A3 (en) | Pharmaceutical methods, dosing regimes and dosage forms for the treatment of alzheimer's disease | |
| RU2008103617A (ru) | Бисфосфоновые кислоты, предназначенные для лечения и профилактики остеопороза | |
| RU2007104774A (ru) | Комбинация анти-вич ингибиторов обратной транскриптазы и протеазы | |
| KR910700045A (ko) | Hiv 감염 관련 질병의 치료 | |
| RU2003125274A (ru) | Применение флумазенила в производстве лекарства для лечения алкогольной зависимости | |
| CO5251425A1 (es) | Metodo y composiciones para administrar taxanos oralmente a pacientes humanos | |
| EP1571155A4 (en) | PEPTIDES AND MEDICAL COMPOSITIONS WITH THE SAME | |
| RU2003127718A (ru) | Применение флумазенила в производстве лекарственного средства для лечения кокаиновой зависимости | |
| MXPA04000007A (es) | Empleo de derivados de acidos 2,5-dihicroxibenceno-sulfonicos en la elaboracion de un medicamento para potenciar el efecto de otros farmacos en el tratamiento de la disfuncion erectil. | |
| AR036009A1 (es) | Composicion farmaceutica para el tratamiento o prevencion del dolor visceral y los trastornos gastrointestinales que comprenden un compuesto aminoácido biciclico y uso de este ultimo para fabricar dicha composicion farmaceutica | |
| UY26595A1 (es) | Formulaciones de entecavir de dosis bajas y uso | |
| RU2005131578A (ru) | Аплидин для лечения множественной миеломы | |
| JP2005505582A5 (ru) | ||
| DK1492539T3 (da) | Statin-terapi til forögelse af kognitiv funktion | |
| MA27474A1 (fr) | Vaccin | |
| DE602004025103D1 (de) | Heilkräuterzusammensetzung zur Behandlung von AIDS | |
| EA200400691A1 (ru) | Получение чистых стереоизомеров трицикло[5,2,1,02,6]дец-9-ил-ксантогената и содержащие их лекарственные средства | |
| DE60114844D1 (de) | Pharmazeutische zusammensetzung und verfahren zur behandlung von retroviralen infektionen |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| MM4A | The patent is invalid due to non-payment of fees |
Effective date: 20100709 |